Dear Editor,

We describe successful recovery from mild COVID-19 in a patient with pancytopenia presenting with neutropenic fever. While lymphopenia has been reported as a common finding in COVID-19, particularly in severe cases, neutropenia has been rarely reported. A case series of over 1000 patients in China observed 83% of patients had lymphopenia but did not report neutropenia, defined as absolute neutrophil count less than 1500 per cubic mm \[[@CR1]\]. A 51-year-old man with NK-cell large granular lymphocytic leukemia complicated by pancytopenia presented with acute fever and cough and was subsequently found to be neutropenic. The patient had stable pancytopenia on a chronic regimen of cyclosporine with no recent bleeding, transfusions, or neutropenia. His exam was notable for a peak temperature of 39.4 °C, bilateral crackles but normal oxygen saturation while breathing room air. Chest x-ray showed bilateral interstitial infiltrate. His labs at presentation were notable for pancytopenia, with mild trilineage decrease compared with baseline (Table [1](#Tab1){ref-type="table"}). His initial absolute neutrophil count (ANC) was 550 per cubic mm, a lifetime nadir. COVID-19 was diagnosed by nasopharyngeal swab with RT-PCR positive for SARS-CoV-2. Negative microbiologic tests included blood cultures, urine culture, and urine antigens for pneumococcus and legionella. He was treated with cefepime, in accordance with guideline recommendations for neutropenic fever, and azithromycin based on initial concern for atypical bacterial community-acquired pneumonia \[[@CR2]\]. Cyclosporine was held throughout the admission and resumed after his first hematology follow-up visit. He was treated with two doses filgrastim (Table [1](#Tab1){ref-type="table"}). Hospital course was uncomplicated and similar to mild courses described in large case series of COVID-19 \[[@CR1], [@CR3], [@CR4]\]. In fact, his time to resolution of dyspnea, time to resolution of fever, and hospital duration were on the low end of the described range (Table [1](#Tab1){ref-type="table"}). Filgrastim was used with the expected neutrophil response and without apparent adverse events, although caution should be employed as endogenous granulocyte stimulating factor has been associated with COVID-19-related cytokine storm \[[@CR5]\]. As COVID-19 spreads among neutropenic patients, further observations regarding the clinical course and response to emerging therapies are necessary to understand the host-virus interaction in this high-risk group.Table 1Trend in fever and complete blood count parameters. "+" indicates the day that COVID-19 RT-PCR became positive. "\*" indicates day a dose of filgrastim was administered. "Baseline" reflects labs acquired at the most recent outpatient visit, 3 weeks prior to presentation. "Follow up" denotes labs acquired 2 weeks post-dischargeBaselineDay of admissionHospital day 1^+^\*Hospital day 2Hospital day 3Hospital day 4Hospital day 5 \*Hospital day\#6Day of dischargeFollow upTmax (°C)\--38.038.738.639.438.839.237.437.1\--White cell count (per mm^3^)34401900201045705140433024505000\--2680Absolute neutrophil count (per mm^3^)124055061032503760290012403010\--560Total lymphocytes (per mm^3^)1780580114089011101120930990\--1700Hemoglobin (g/deciliter)10.910.59.410.510.510.610.39.8\--8.6Platelets (per mm^3^)83,00056,00044,00048,00042,00043,00044,00038,000\--22,000
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